Acute Stroke Management in Türkiye: Intravenous Tissue Plasminogen Activator and Thrombectomy NöroTek: Türkiye Neurology Single Day Study

Basit Öğe Kaydı
dc.authoridAtmaca, Murat Mert/0000-0003-2048-4930
dc.authoridKablan, Yüksel/0000-0002-5581-2968
dc.authoridILGEZDI, IREM/0000-0001-5376-9700
dc.authoridSarionder Gencer, Elif/0000-0003-3881-9559
dc.authoridGULER, AYSE/0000-0003-4465-3743
dc.authoridARSLAN, YILDIZ/0000-0001-8818-9423
dc.authoridYılmaz, Arda/0000-0002-4679-1632
dc.authorwosidAtmaca, Murat Mert/AGB-2783-2022
dc.authorwosidAfsar, Nazire/S-8639-2016
dc.authorwosidbas, demet funda/D-3646-2015
dc.authorwosidKablan, Yüksel/AAB-5049-2021
dc.authorwosidILGEZDI, IREM/KHX-9697-2024
dc.authorwosidKaya, Dilaver/W-9348-2018
dc.authorwosidSarionder Gencer, Elif/AAD-2703-2019
dc.contributor.authorTopcuoglu, Mehmet Akif
dc.contributor.authorOzdemir, Atilla Ozcan
dc.contributor.authorArsava, Ethem Murat
dc.contributor.authorGunes, Aygul
dc.contributor.authorAykac, Özlem
dc.contributor.authorGencer, Elif Sarionder
dc.contributor.authorCabalar, Murat
dc.date.accessioned2024-08-04T20:54:57Z
dc.date.available2024-08-04T20:54:57Z
dc.date.issued2023
dc.departmentİnönü Üniversitesien_US
dc.description.abstractObjective: To reveal the profile and practice in patients with acute stroke who received intravenous tissue plasminogen activator (IV tPA) and/or neurointerventional therapy in Turkiye. Materials and Methods: On World Stroke Awareness Day, May 10, 2018, 1,790 patients hospitalized in 87 neurology units spread over 30 health regions were evaluated retrospectively and prospectively. Results: Intravenous tPA was administered to 12% of 859 cases of acute ischemic stroke in 45 units participating in the study. In the same period, 8.3% of the cases received neurointerventional treatment. The rate of good prognosis [modified Rankin score (mRS) 0-2] at discharge was 46% in 83 patients who received only IV tPA [age: 67 +/- 12 years; National Institutes of Health Stroke Scale (NIHSS): 12 +/- 6; hospital stay, 24 +/- 29 days]; 35% in 51 patients who underwent thrombectomy (MT) alone (age: 64 +/- 13 years; NIHSS: 14.1 +/- 6.5; length of hospital stay, 33 +/- 31 days), 19% in those who received combined treatment (age: 66 +/- 14 years; NIHSS: 15.6 +/- 5.4; length of hospital stay, 26 +/- 35 days), and 56% of 695 patients who did not receive treatment for revascularization (age: 70 +/- 13 years; NIHSS: 7.6 +/- 7.2; length of hospital stay, 21 +/- 28 days). The symptom-to-door time was 87 +/- 53 minutes in the IV treatment group and 200 +/- 26 minutes in the neurointerventional group. The average door-to-needle time was 66 +/- 49 minutes in the IV tPA group. In the neurothrombectomy group, the door-to-groin time was 103 +/- 90 minutes, and the TICI 2b-3 rate was 70.3%. In 103 patients who received IV tPA, the discharge mRS 0-2 was 41%, while the rate of mRS 0-1 was 28%. In 71 patients who underwent neurothrombectomy, the mRS 0-2 was 31% and mRS 0-1 was 18%. The door-to-groin time was approximately 30 minutes longer if IV tPA was received (125 +/- 107 and 95 +/- 83 minutes, respectively). Symptomatic bleeding rates were 4.8% in IV recipients, 17.6% among those who received only MT, and 15% in combined therapy. Globally, the hemorrhage rate was 6.8% in patients receiving IV tPA and 16.9% in MT. Conclusion: IV thrombolytic and neurointerventional treatment applications in acute ischemic stroke in Turkiye can provide the anticipated results. Heterogeneity has begun to be reduced in our country with the dissemination of the system indicated by the Directive on Health Services to be Provided to Patients with Acute Stroke.en_US
dc.identifier.doi10.4274/tnd.2023.70292
dc.identifier.endpage255en_US
dc.identifier.issn1301-062X
dc.identifier.issn1309-2545
dc.identifier.issue4en_US
dc.identifier.scopus2-s2.0-85180871690en_US
dc.identifier.scopusqualityQ4en_US
dc.identifier.startpage249en_US
dc.identifier.urihttps://doi.org/10.4274/tnd.2023.70292
dc.identifier.urihttps://hdl.handle.net/11616/101744
dc.identifier.volume29en_US
dc.identifier.wosWOS:001137624800014en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherGalenos Publ Houseen_US
dc.relation.ispartofTurkish Journal of Neurologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectAcute strokeen_US
dc.subjectthrombolytic therapyen_US
dc.subjectthrombectomyen_US
dc.subjectprognosisen_US
dc.subjecttreatment windowen_US
dc.subjectmetricen_US
dc.titleAcute Stroke Management in Türkiye: Intravenous Tissue Plasminogen Activator and Thrombectomy NöroTek: Türkiye Neurology Single Day Studyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu